Comparison of the efficacy of irsogladine maleate and famotidine for the healing
of gastric ulcers after Helicobacter pylori eradication therapy: a randomized,
controlled, prospective study.
Author(s): Murakami K, Okimoto T, Kodama M, Tanahashi J, Mizukami K, Shuto M, Abe H, Arita
T, Fujioka T.
Affiliation(s): Department of Gastroenterology, Faculty of Medicine, Oita University, 1-1
Idaigaoka, Hasama-machi, Yufu, Oita, Japan. murakam@med.oita-u.ac.jp
Publication date & source: 2011, Scand J Gastroenterol. , 46(3):287-92
OBJECTIVE: Helicobacter pylori eradication therapy alone cannot heal gastric
ulcers in Japanese patients. Irsogladine has previously been shown to accelerate
the healing of gastric ulcers after H. pylori eradication therapy. And we
previously reported that histamine H(2) receptor antagonists inhibit gastric
ulcer relapse after H. pylori eradication therapy. We therefore compared the
efficacy of irsogladine with famotidine as appropriate treatments for ulcers
after eradication therapy.
METHODS: Gastric ulcer patients with H. pylori infection (n = 119) were
randomized to treatment with irsogladine 4 mg/day (n = 60) or famotidine 40
mg/day (n = 59) following 1-week H. pylori eradication therapy. After treatment,
assessments of gastric ulcer healing were performed.
RESULTS: The ulcer healing rates in patients receiving irsogladine and famotidine
were 85.2% (46/54) and 79.6% (43/54), respectively, and were not significantly
different (p = 0.4484). In the famotidine group, the healing rate was
significantly lower in patients who drink alcohol than in those who do not (60.0%
vs. 91.2%; p = 0.0119). However, in the irsogladine group the healing rate did
not differ between patients who drink alcohol and those who do not. Furthermore,
the healing rate in smokers was significantly higher in the irsogladine group
(88.0%) than in the famotidine group (59.1%) (p = 0.0233).
CONCLUSIONS: Irsogladine and famotidine are both acceptable in treatment after H.
pylori eradication therapy in gastric ulcer patients. Findings also suggest that
irsogladine is more beneficial than famotidine in patients who drink alcohol and
smoke.
|